DSHEA Weekly Digest – November 17, 2026


DSHEA Weekly Digest – November 17, 2026

DSHEA Preservation Alliance

Weekly Digest

November 17, 2026

Volume 8, Issue 3

What’s Inside This Week

FDA's proposal to make N-acetyl-L-cysteine (NAC) a lawful dietary supplement ingredient leads this week. It is the first time the agency has used its rulemaking authority under the drug exclusion clause, and it opens a 60-day comment period that will shape how that authority is used for other ingredients. Trade groups welcomed the move but disagree on whether it proves the statute works or shows why Congress should rewrite it. Also inside are new FDA recalls of products spiked with undeclared drugs, a pending federal restriction on concentrated 7-OH products, California's date labeling exemption for supplements, age restrictions reaching creatine, a US and China ingredient verification initiative, a major multivitamin evidence review, and survey data showing rising consumer doubt about supplements.

 

NAC & the Drug Exclusion Clause

FDA Proposes Rule to Allow NAC as a Dietary Supplement Ingredient

Nutritional Outlook  |  November 16, 2026

FDA proposed a rule on November 16 that would reverse the exclusion of N-acetyl-L-cysteine (NAC) from the dietary supplement definition, the agency's first use of its rulemaking authority under the exclusion provision that DSHEA added to the Federal Food, Drug, and Cosmetic Act. The draft would create a new regulation, 21 CFR 190.1, listing NAC as the first ingredient not excluded and reserving space for future additions. FDA said its peer-reviewed safety assessment of 41 studies found minimal concern, and comments are due 60 days after Federal Register publication in Docket FDA-2025-N-2699.

FDA proposes NAC supplement rule amid drug preclusion debate

NutraIngredients  |  November 17, 2026

Trade groups welcomed the NAC proposal but split on what it means for the wider drug preclusion fight. The Natural Products Association credited its 2021 citizen petition and said the outcome shows the existing statute works, while the Council for Responsible Nutrition and the American Herbal Products Association said FDA offered no process for other ingredients and pointed to the Dietary Supplement Innovation Act as the legislative fix. FDA will keep its 2022 enforcement discretion policy in place while the rulemaking proceeds.

FDA Proposes Rule to Reverse NAC Drug Preclusion

Nutraceuticals World  |  November 17, 2026

This report traces the dispute from FDA's 2020 warning letters, which cited NAC's 1963 drug approval, through the citizen petitions and litigation that followed. NPA President Daniel Fabricant called the proposal an important precedent and linked it to the association's earlier work on NMN. The piece also notes that NAC, NMN and CBD have together driven the debate over how FDA applies the race-to-market test in the statute.

 

FDA Enforcement & Safety

Sexual Enhancement Honey and Capsules Recalled for Hidden Sildenafil and Tadalafil That Can Endanger Men on Nitrates

Medical Daily  |  November 13, 2026

Two products sold for male sexual enhancement were recalled after FDA testing found undeclared prescription drugs, with recall notices posted November 12. Game Changer Products recalled all lots of 10 Day Forecast capsules for sildenafil and acetaminophen, and Eros Apothecary recalled one batch of Candy Power For Man Organic Honey for tadalafil. Products spiked with drug ingredients cannot be marketed as dietary supplements, and FDA says its public list of tainted products covers only a small fraction of what is sold online.

Kratom and 7-OH can feel like 'a miracle.' They can also be addictive

NPR (via KPBS)  |  November 13, 2026

A federal restriction on concentrated 7-hydroxymitragynine (7-OH) products could take effect as early as November 13, following a revised HHS recommendation issued October 9 that narrowed the Drug Enforcement Administration's approach to higher-concentration products. Federal officials say traditional botanical kratom is not the target. The story matters for the supplement sector because these products are sold over the counter alongside supplements, and regulators are turning to drug scheduling to separate a botanical from its concentrated derivatives.

 

State Policy & Market Access

California Exempts Supplements From Food Date Labeling, but Expiration Dates Still Need Proof

Nutritional Outlook  |  November 12, 2026

California's AB 2779 removes dietary supplements from the state's standardized food date labeling law, which would have pushed products toward best-by language. Todd Harrison of Venable LLP says the exemption is correct but warns that expiration dates still require stability testing or a sound scientific rationale, and that brand owners remain responsible for label claims and contract manufacturer compliance. He argues that the growing patchwork of state laws strengthens the case for Congress to set uniform national rules.

Creatine in 2026: 9 big takeaways from SupplySide Global

SupplySide Supplement Journal  |  November 11, 2026

Creatine is now age-restricted under New York's law on muscle-building and weight-loss supplements, and some major retailers have stopped shipping it to the state. California's AB 2030 takes effect January 1 and, unlike New York's law, does not exempt protein or fiber. The report also notes that the Council for Responsible Nutrition raised its highest observed intake for adults from 5 to 10 grams per day, a safety benchmark drawn from 162 clinical studies.

 

Industry, Science & Consumer Trust

UNPA, Chinese Groups Announce Initiative on Botanical Ingredient Verification

Nutritional Outlook  |  November 13, 2026

The United Natural Products Alliance and two Chinese trade organizations launched a voluntary initiative to improve verification of botanical ingredients sourced from China. A pilot will test a shared quality and trade protocol on real ingredient lots, targeting adulteration and inconsistent documentation. The effort speaks directly to the identity and quality obligations that manufacturers carry under federal good manufacturing practice rules.

Supplement Shorts: Multivitamins support nutrition but do not prevent disease, review finds

SupplySide Supplement Journal  |  November 13, 2026

A scoping review in the Journal of Dietary Supplements finds that the most consistent benefit of multivitamins is improved circulating folate, vitamin B6 and vitamin B12, while clinical benefits vary by formulation and population. Lead author Taylor Wallace said improving a nutrient biomarker and preventing a clinical disease are different objectives. That distinction tracks the line DSHEA draws between permitted structure and function claims and prohibited disease claims.

Thorne Survey Compares Consumer Trust in AI, Influencers, and Credentialed Experts

Nutritional Outlook  |  November 12, 2026

A Censuswide survey of 3,004 US consumers commissioned by Thorne found that the share who agree supplements are a scam rose from 24% to 35% in one year. Half of respondents now trust AI tools for wellness advice, and 45% said they do not feel confident choosing supplements for themselves. The findings point to a credibility gap that quality standards, truthful labeling and enforcement against bad actors are meant to close.

Your Voice Matters

FDA is accepting public comments on its proposed NAC rule for 60 days after publication in the Federal Register (Docket FDA-2025-N-2699). The agency is asking for input on evidence of early marketing, effects on drug development, the effective date and its cost estimates. This is the first rulemaking of its kind under the exclusion clause, and the record built now will guide how the authority is used in the future.

Read the Proposal and Comment

DSHEA.org  | 
About  | 
Issues  | 
Media & Newsroom

DSHEA Preservation Alliance
*|LIST:ADDRESSLINE|*

Unsubscribe  |  Update preferences

Powered by PICXM